Across TCGA pan-cancer cohorts, PPIL6 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PPIL6 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PPIL6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPIL6 expression acts as an unfavorable survival marker.

BLCA and COAD are the cancer types where PPIL6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.100	0.626	<.001	18	view →
COAD	OS	Median	All	0.464	0.873	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PPIL6 tumor-vs-normal RNA expression · all PPIL6 data types